187 results on '"Fasani R"'
Search Results
2. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer
3. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
4. EP14.04-02 Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients (p)
5. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
6. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade
7. DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
8. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
9. 62P KI67 in ER+HER2-negative pure invasive lobular breast carcinoma (ILC). What’s the best Ki67 threshold to differentiate prognosis?
10. 790P The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs)
11. 579P Intratumoral fusobacterium as prognostic factor in early stage colorectal cancer: Results of the FUSOMAP study
12. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)
13. 87P EPClin vs OncotypeDx in invasive lobular cancer (ILC)
14. Mitochondrial DNA Mutations and Cardiomyopathies
15. 2314P Quality and safety of research biopsies (RB) in oncology clinical trials
16. Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)
17. P-268 Using 16S rRNA gene sequencing to investigate the composition of Fusobacterium-associated microbiota and its impact on outcome in rectal cancer
18. 487P Use of patient-derived tumour organoids to identify acquired treatment resistance and determine optimal post-progression combinations in metastatic colorectal cancer
19. 581P VHIO immune gene expression profiling (VIGex) panel, a tool to explore tumour immune microenvironment
20. 8P Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)
21. 4O VHIO immune gene expression profiling (VIGex) panel, a tool to explore tumor immune microenvironment
22. Neuroendocrine carcinoma of the vulva with paraganglioma-like features
23. PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
24. VHIO-300 and a thousand and one nights: A tale of precision medicine
25. Prospective pathological experience with research biopsies in the context of clinical trials at Vall d’Hebron Institute of Oncology
26. Abstract P6-17-08: Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy
27. Coexistence of mitochondrial DNA and beta myosin heavy chain mutations in hypertrophic cardiomyopathy with late congestive heart failure
28. Dissecting the antitumor immune response upon PARP inhibition in homologous recombination repair (HRR)-deficient tumors
29. Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)
30. Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer
31. Abstract P2-09-14: A predictive model of pathological response following dual HER2 blockade-only based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer
32. Fortuitous diagnosis of cystic fibrosis at laparotomy for acute appendicitis
33. Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
34. Abstract P6-07-16: Quantitative proteomic analysis of FGFR by mass spectrometry may improve identification of FGFR amplified tumors sensitive to inhibitor therapy
35. Abstract S3-03: PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial
36. 2027P - VHIO-300 and a thousand and one nights: A tale of precision medicine
37. 1886P - Prospective pathological experience with research biopsies in the context of clinical trials at Vall d’Hebron Institute of Oncology
38. 1873O - PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
39. Der Dichter Remo Fasani: Worte der Stille im Lärm der Welt
40. 18P - Dissecting the antitumor immune response upon PARP inhibition in homologous recombination repair (HRR)-deficient tumors
41. 143P - Tumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT)
42. 440 (PB-073) - Tumor-infiltrating lymphocytes density correlates with HER2 gene copy number but not with protein levels in HER2-positive breast cancer
43. Immunoreactivity for cyclin D3 is frequently detectable in high-grade primary gastric lymphoma in the absence of the t(6;14)(p21.1;q32.3) translocation
44. Single dose bioavailability and pharmacokinetic study of a innovative formulation of α-lipoic acid (ALA600) in healthy volunteers
45. 155PD - Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
46. Spermatic cord liposarcoma: A report of four cases
47. The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium
48. Human cytomegalovirus early infection, acute rejection, and major histocompatibility class II expression in translanted lung. Molecolar, immunocytochemical, and histopathologic investigations
49. Effects of Kallikrein on the Male Reproductive System and its Use in the Treatment of Idiopathic Oligozoospermia with Impaired Motility
50. The Treatment of Male Subfertility with Kallikrein
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.